U.S. Blood Collection Market Size, Share & Trends Analysis Report By Site (Venous, Capillary), By Application (Diagnostics, Treatment), By End Use, By Age, By Demography, By States, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The U.S. blood collection market size was estimated at USD 1.18 billion in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. The rising demand for blood collection products is owing to an increase in the number of diagnostic procedures involving blood samples. These procedures include disease screenings and medication monitoring. In addition, regular blood tests are necessary for treatment evaluation & monitoring of chronic illnesses, such as diabetes, cardiovascular disease, and cancer. High efficiency and ease in ensuring precise sample collection & preservation make these tests popular among medical experts.

Moreover, the increasing prevalence of chronic and infectious diseases is a major factor driving the use of blood collection devices. With the U.S. becoming more globalized, health risks transcend borders. Economic integration, industrialization, urbanization, and mass migration contribute to various public health challenges. In addition, the increasing prevalence of chronic diseases, such as diabetes and cardiovascular diseases, is expected to drive the demand for blood collection devices. These conditions require regular testing and monitoring, making reliable blood collection methods indispensable in managing them effectively. As per CDC data, approximately 38 million adults were suffering from diabetes in 2022. In addition, obesity is linked to up to 53% of new type 2 diabetes cases annually. Thus, the increasing prevalence of diabetes is expected to boost the demand for vacutainers in recurring diagnostic tests, such as blood sugar assays.

Furthermore, the rise in antimicrobial resistance and the potential for infectious diseases to re-emerge emphasize the importance of robust collection systems for timely diagnosis & treatment.

Percentage of adults aged ≥18 years with diagnosed heart disease by age group and urbanization level in the U.S. in 2020

Furthermore, the rising number of blood transfusions is a key driver for the U.S. blood collection market. According to the National Blood Collection and Utilization Survey (NBCUS), the U.S. observed a 1.7% increase in Red Blood Cell (RBC) units collected between 2019 and 2021. In 2021, 11.78 million RBC units were collected, while 10.76 million RBC units were transfused. Moreover, the number of whole blood units collected for allogeneic, nondirected donations in 2021 increased by 0.7% to 9.84 million units, and the number of apheresis RBC units collected rose by 7.3% to 1.93 million units. Every 2 seconds, someone in the U.S. needs blood or platelets, highlighting the constant demand for these products. Approximately 29,000 units of RBCs are required daily in the U.S., along with nearly 5,000 units of platelets and 6,500 units of plasma. In total, almost 16 million blood components are transfused each year in the U.S.

The rising incidence of hematological disorders is a significant factor driving the use of these collection devices. The prevalence of hematologic diseases, including anemia; sickle cell disease; bleeding disorders, such as clots & hemophilia; and cancer types, including myeloma, lymphoma, & leukemia, is growing. For example, in the U.S., every 9 minutes, someone dies from blood cancer, representing about 157 people each day or more than six people every hour. Leukemia, lymphoma, and myeloma are expected to cause the deaths of an estimated 57,380 people in the U.S. in 2023, accounting for 9.4% of cancer deaths that year.

Moreover, an estimated 437,337 people are living with or in remission from leukemia, and an estimated 879,242 people are living with or in remission from lymphoma in the U.S. Furthermore, approximately 900,000 people in the U.S. develop blood clots annually, and clots are responsible for approximately 100,000 deaths each year. It is worth noting that fewer than one in four people show any recognizable signs and symptoms of a blood clot.

Industry Dynamics

The U.S. blood collection industry exhibits a moderate level of concentration. Characteristics include rapid technological advancements, such as self-administered microsampling tools. These tools enable individuals to perform fingerstick collection easily at home, work, or at the point of care, eliminating the need for a trained phlebotomist. The industry showcases continuous innovation and expansion fueled by the growing number of transfusions and the growing adoption of healthcare solutions.

The market is characterized by a high degree of innovation, driven by advancements in developing innovative materials and technologies for low-volume blood collection, ensuring high precision and mitigating the effects of hematocrit variations. For instance, hemaPEN offers enhanced flexibility for blood sampling compared to traditional phlebotomy methods. It enables collecting and storing four Dried Blood Spot (DBS) samples through a convenient and user-friendly procedure. Unlike conventional DBS tools, the hemaPEN ensures the collection of accurate and precise fixed micro volumes, maintaining sample integrity for quantitative analysis.

The U.S. market is witnessing a moderate level of mergers and acquisitions (M&A) activity, reflecting a trend toward consolidation within the broader blood collection and healthcare sector. Larger companies are collaborating to expand their product portfolios and enhance their technological capabilities. For instance, in October 2021, Terumo Blood and Cell Technologies inaugurated a new manufacturing facility in La Lima, Cartago, Costa Rica, with an investment of USD 60 million aimed at expanding the company’s patient service capabilities.

Regulations play a crucial role in shaping the U.S. market, influencing everything from the approval of new medications and devices to the standards of care provided. Regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) oversee the approval process for veterinary pharmaceuticals and medical devices, ensuring their safety and efficacy. For instance, in March 2024, the U.S. FDA granted 510(k) clearance to RedDrop Dx, Inc. for the RedDrop One, an innovative blood collection device for prescription use. This milestone represents a significant advancement in collection technology and patient care for the company. RedDrop One provides numerous advantages over traditional methods, including collecting a larger volume of blood with greater ease and reliability while minimizing user discomfort.

Companies are expanding their operations and investing in local partnerships to tap into these burgeoning markets. For instance, in May 2022, Terumo Corporation opened a state-of-the-art manufacturing facility in Douglas County, Colorado, representing a USD 250 million investment. This new plant underscores the company's commitment to advancing healthcare and expanding patient care capabilities as part of its mission to contribute to society.

Site Insights

The venous segment dominated the market with a revenue share of 82.3% in 2023 and is expected to grow at the fastest CAGR over the forecast period. The segment is primarily driven by the increasing prevalence of chronic diseases and the growing need for accurate diagnostic testing. Patients prefer the venous route for blood collection for laboratory tests due to its several advantages. This technique allows the collection of a higher volume of samples, reduces pain & discomfort, and lowers the risk of hemolysis, making it a dependable and efficient way to obtain samples. Venous blood collection is a significant segment of the blood collection market due to its reliability and efficiency in obtaining high-quality samples. The demand for the venous segment is rising due to the increasing prevalence of chronic diseases and the growing need for accurate diagnostic testing.

The capillary segment is anticipated to grow at a lucrative rate over the forecast period. The growth is driven by its offering of numerous advantages in phlebotomy. It is less invasive, simple to execute, and poses fewer risks compared to venipuncture. The procedure requires minimal equipment and is less painful, providing a more comfortable experience for patients. Its suitability for patients of all ages and the ability to be performed in various settings make capillary blood collection a versatile and valuable technique in healthcare.

Application Insights

The diagnostics segment dominated the market in 2023 and is expected to grow at the fastest CAGR over the forecast period, owing to its accurate assessment and management of various medical conditions. Technological advancements have revolutionized diagnostic capabilities, enabling more precise and rapid testing for a wide range of medical conditions. The shift toward personalized medicine and genomic testing has expanded the scope of diagnostic services, catering to individual patient needs and improving treatment outcomes. In addition, the increasing prevalence of chronic diseases, such as diabetes and cardiovascular conditions, necessitates frequent monitoring and early detection through diagnostic testing, boosting market demand. For instance, Chronic Obstructive Pulmonary Disease (COPD) & asthma, which are prevalent chronic respiratory conditions, require blood tests to assess gas exchange & inflammation, among other parameters.

The treatment segment is anticipated to grow at a lucrative CAGR over the forecast period. These products are used for the treatment of various disorders, including chronic kidney disorders, various types of cancer, autoimmune disorders, and neurological conditions. A patient may require transfusion of blood or components-such as platelets, plasma, and granulocytes-during the treatment of a severe infection or after blood loss during surgery or post-injury. The demand for blood and components is high due to the increasing number of surgeries and accidents globally. In addition, the demand for blood during the treatment of cancer has increased.

End Use Insights

The hospitals segment dominated the market with a share of 28.3% in 2023. This growth is owed to the high number of cases and diagnostic tests being conducted. With the rise in the number of surgical procedures such as angioplasty and kidney & liver transplants and the growing incidence of trauma, the requirement for blood transfusion has significantly increased in hospitals. In addition, there is a significant demand for diagnosis of several diseases, including cancer, heart or lung diseases, sickle cell anemia, and disorders such as thalassemia & hemophilia. There has been a significant increase in the prevalence of infectious diseases such as malaria, dengue, hepatitis, and pneumonia, which require capillary blood collection devices for early detection & diagnosis.

The blood bank centers segment is anticipated to grow at a significant rate over the forecast period. The growth is attributed to government initiatives and support for blood donation programs & blood safety. Policies and funding to enhance collection and transfusion services influence the adoption of advanced sample collection products, including vacuum blood collection tubes. For instance, in August 2022, the U.S. Department of Health and Human Services announced a new campaign to increase U.S. blood and plasma donations. The campaign aimed to increase awareness about the importance of donating blood and encourage citizens to be accustomed to donating blood.

Age Insights

The 19 to 65 segments held the largest market share in 2023 and are expected to grow at the fastest CAGR over the forecast period. The growth is attributed to the increasing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, which require regular blood testing for effective management. Increasing awareness and emphasis on preventive healthcare further boosts demand for routine tests, including cholesterol & glucose monitoring. Technological advancements in blood collection methods, such as less invasive techniques and improved POCT, enhance patient compliance and fuel market growth. Furthermore, healthcare policies promoting regular health check-ups and screenings contribute to higher test volumes.

The 0-18 segment is anticipated to grow at a significant CAGR over the forecast period. The growth is driven by the increasing prevalence of infectious diseases such as pneumonia, diarrhea, malaria, and sepsis, necessitating frequent diagnostic testing and boosting demand for collection services. Children under the age of 5 are especially susceptible to infectious diseases such as malaria, pneumonia, diarrhea, HIV, and tuberculosis.

Demography Insights

The urban segment dominated the market in 2023 and is expected to grow at the fastest CAGR over the forecast period, owing to the presence of a well-established hospital infrastructure and a large number of diagnostic laboratories in the region. Between 2010 and 2020, the urban population in the U.S. grew by 6.4%, according to the 2020 Census, driven partly by a redefinition of urban areas. Globally, urbanization has been ongoing since the 18th century Industrial Revolution, with the United Nations estimating that 3.9 billion people now live in urban centers.

The rural segment is anticipated to grow at a lucrative CAGR during the forecast period. Chronic disease presents a significant challenge to rural healthcare systems and residents in the U.S., impacting quality of life, mortality rates, and healthcare expenditure. Compared to urban areas, rural communities often lack resources for effective prevention and treatment of chronic diseases. This disparity is compounded by higher prevalence rates of multiple chronic conditions among rural populations, which are both complex to manage and costly to treat.

Key U.S. Blood Collection Company Insights

The market is highly competitive. Key companies deploy strategic initiatives, such as service development, launches, and sales & marketing strategies to increase product awareness and regional expansions and partnerships to strengthen their market share. Market players are also involved in conducting clinical testing of their procedures, patent applications, and increasing service penetration.

Recent Developments

• In May 2024, the U.S. FDA approved the Rika Plasma Donation System featuring the iNomi Nomogram developed by Terumo Corporation. This product helps determine plasma collection volume based on an individual donor's weight, height, and hematocrit level at the time of donation.

• In December 2023, BD received 510(k) clearance from the U.S. FDA for the BD MiniDraw Capillary Blood Collection System. The BD MiniDraw Capillary Blood Collection System provides a less invasive alternative to traditional venous blood draws.

• In February 2023, Terumo Corporation's IMUGARD WB Platelet Pooling Set received clearance from the U.S. FDA to be launched in the market. This innovative set extends the shelf life of whole blood-derived platelets from 5 days to 7 days, enhancing operational efficiency and product availability

U.S. Blood Collection Market Report Scope

U.S. Blood Collection Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. blood collection market report based on site, application, end use, age, and demographic. 

• Site Outlook (Volume, Units in Million; Revenue, USD Million, 2018 - 2030)

  • Venous

    • Needles and Syringes

      • Double-Ended Needles

      • Winged Blood Collection Sets

      • Standard Hypodermic Needles

      • Other Blood Collection Needles

    • Blood Collection Tubes

      • Serum-separating

      • EDTA

      • Heparin

      • Plasma-separating

    • Blood Bags

    • Others

  • Capillary

    • Lancets

    • Micro-Container Tubes

    • Micro-Hematocrit Tubes

    • Warming Devices

    • Others

• Application Outlook (Volume, Units in Million; Revenue, USD Million, 2018 - 2030)

  • Diagnostics

  • Treatment

• End Use Outlook (Volume, Units in Million; Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Clinical Laboratories

  • Blood Banks Centers

  • Clinics

  • Mobile Service

  • Emergency Departments

  • Others

• Age Outlook (Volume, Units in Million; Revenue, USD Million, 2018 - 2030)

  • 0-18

  • 19 to 65

  • 66 years and above

• Demography Outlook (Volume, Units in Million; Revenue, USD Million, 2018 - 2030)

  • Urban

  • Rural

• States Outlook (Volume, Units in Million; Revenue, USD Million, 2018 - 2030)

  • California

  • Texas

  • Florida

  • New York

  • Pennsylvania

  • Illinois

  • Ohio

  • Georgia

  • North Carolina

  • South Carolina

  • Michigan

  • Alabama

  • Arkansas

  • Kentucky

  • Louisiana

  • Mississippi

  • Tennessee

  • West Virginia

  • Virginia

  • Colorado

  • Alaska

  • Vermont

  • South Dakota

  • Maine

  • Oregon

  • Rest of U.S.